Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 5OTHER 4NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 2

Conditions

Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

Cytarabine 30fludarabine phosphate 19Specimen Handling 15Cyclophosphamide 15Biopsy 14Peripheral Blood Stem Cell Transplantation 13Busulfan 13Imatinib Mesylate 12Etoposide 12Filgrastim 11Decitabine 11Azacitidine 11Methotrexate 10Idarubicin 10Daunorubicin 10Cyclosporine 9X-Rays 8Tacrolimus 8Antilymphocyte Serum 8tipifarnib 7Vorinostat 7Stem Cell Transplantation 7Radiotherapy 7Magnetic Resonance Spectroscopy 7fludarabine 6decitabine and cedazuridine drug combination 6Phantoms, Imaging 6Topotecan 5Prednisone 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Homoharringtonine × Myeloid × Clear all
NCT00003694 2013-06-05

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00006364 2013-01-23

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡